Moderna has reported preliminary clinical ... "We believe that a bivalent booster vaccine, if authorised, would create a new tool as we continue to respond to emerging variants," added Bancel.

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

More than 1,500 people who have sought support from the vaccine damage payment scheme after being injured or bereaved as a ...

researchers recommended that people who received it get a second booster dose with an mRNA vaccine such as Moderna and Pfizer. According to the published results, there were 129 coronavirus ...

Moderna provided an update on the status of its trial investigating a vaccine candidate for norovirus in a company statement on Monday.

Robert F. Kennedy Jr. made claims during his Senate confirmation hearing on issues including vaccines, pesticides and Lyme ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

SINGAPORE - People who are eligible for the Novavax Covid-19 vaccine can go to selected clinics from Jan 24 to April 30 for ...

Moderna, Inc. (NASDAQ:MRNA) today announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine in the European Union (EU), Norway and North Macedonia. Under the resulting ...

Through the first nine months of 2024, Moderna's revenue of $2.3 billion represents a 44% decline year over year. This figure includes a mere $10 million in sales of the new RSV vaccine following ...